Belinostat, the third approved HDAC inhibitor, is used in peripheral T cell lymphoma (PTCL) treatment, while Panobinostat was the fourth HDAC inhibitor approved for treating multiple myeloma. The gene discussed is HDAC9; the disease is peripheral T-cell lymphoma, not otherwise specified.